SGLT2 inhibitor use was also associated with increased risk for mortality in those with type 2 diabetes mellitus and either multiple myeloma or acute myeloid leukemia, independent of congestive heart failure. This evidence concerns the gene SLC5A2 and AL amyloidosis.